Gilead Sciences Inc has filed an application with the US Food and Drug Administration seeking full approval for remdesivir, its experimental Covid-19 drug currently used under emergency authorization, the drugmaker said on Monday.
The antiviral drug, which helped shorten the hospital recovery time in a US trial, has been at the forefront of the battle against the pandemic after the FDA granted it emergency use authorization (EUA) in May.
The authorization cleared the way for broader use of the drug in more hospitals around the United States, which has recorded over 162,600 Covid-19 deaths and over 5 million infections. But